B-Cell-Mediated Strategies to Fight Chronic Allograft Rejection by Ali Dalloul
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 17 December 2013
doi: 10.3389/fimmu.2013.00444
B-cell-mediated strategies to fight chronic allograft
rejection
Ali Dalloul*†
INSERM U 996, Clamart, France
Edited by:
Seiamak Bahram, Université de
Strasbourg, France
Reviewed by:
Reem Al-Daccak, INSERM, France
Takuya Ueno, Harvard Medical School,
USA
*Correspondence:
Ali Dalloul , INSERM U 996, 32 Rue
des Carnets, Clamart 92140, France
e-mail: ali.dalloul@u-psud.fr
†Alternative address:
Ali Dalloul , Thérapie Cellulaire, CHU,
Nancy, France
e-mail: ali.dalloul@univ-lorraine.fr
Solid organs have been transplanted for decades. Since the improvement in graft selection
and in medical and surgical procedures, the likelihood of graft function after 1 year is now
close to 90%. Nonetheless even well-matched recipients continue to need medications for
the rest of their lives hence adverse side effects and enhanced morbidity. Understanding
Immune rejection mechanisms, is of increasing importance since the greater use of living-
unrelated donors and genetically unmatched individuals. Chronic rejection is devoted to
T-cells, however the role of B-cells in rejection has been appreciated recently by the obser-
vation that B-cell depletion improve graft survival. By contrast however, B-cells can be
beneficial to the grafted tissue. This protective effect is secondary to either the secretion
of protective antibodies or the induction of B-cells that restrain excessive inflammatory
responses, chiefly by local provision of IL-10, or inhibit effectorT-cells by direct cellular inter-
actions. As a proof of concept B-cell-mediated infectious transplantation tolerance could
be achieved in animal models, and evidence emerged that the presence of such B-cells
in transplanted patients correlate with a favorable outcome. Among these populations,
regulatory B-cells constitute a recently described population. These cells may develop as
a feedback mechanism to prevent uncontrolled reactivity to antigens and inflammatory
stimuli. The difficult task for the clinician, is to quantify the respective ratios and functions
of “tolerant” vs. effector B-cells within a transplanted organ, at a given time point in order
to modulate B-cell-directed therapy. Several receptors at the B-cell membrane as well as
signaling molecules, can now be targeted for this purpose. Understanding the tempo-
ral expansion of regulatory B-cells in grafted patients and the stimuli that activate them
will help in the future to implement specific strategies aimed at fighting chronic allograft
rejection.
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INTRODUCTION
Kidneys have been the most frequently transplanted organs for
decades. Since the improvements in graft selection and in med-
ical and surgical procedures, the likelihood of graft function after
1 year is now close to 90%. Nonetheless even well-matched recip-
ients continue to need medications for the rest of their lives
hence adverse side effects and enhanced morbidity. The half-
life of transplanted kidneys is still below 10 years indicating a
continuous deterioration of the organ due to combined meta-
bolic and immunologic rejection mechanisms. The later are of
increasing importance since the greater use of living-unrelated
donors and genetically unmatched individuals. Chronic rejec-
tion is not specific of kidney transplants but works equally in
other grafts and depends on HLA matching. Chronic rejec-
tion is mediated by T-cells and often successfully prevented by
immunosuppressive drugs aimed at inhibiting T-cell prolifera-
tion. However the role of B-cells in chronic rejection has been
appreciated recently in patients and in experimental models. Fur-
thermore, the finding that B-cells can also, be beneficial to the
grafted tissue generated great interest. This “tolerizing effect”
occurs either through the secretion of protective antibodies or
through induction of – recently described – regulatory B-cells and
secondary induction of regulatory T-cells.
THE ROLE OF B-CELLS IN TRANSPLANT REJECTION
Acute and hyperacute rejection are mediated by preformed or by
induced antibodies
Induced antibodies. MHC (HLA) antigens and minor antigens
that behave like nominal antigens and are presented by HLA mol-
ecules to T-cells, are responsible for T-cell alloreactivity. These
new determinants expressed on donor tissue ultimately lead to the
formation of new antibodies directed at MHC antigens. This T-
cell-dependent response generates IgM and then converts to IgG
production. These Abs are not responsible for acute graft rejec-
tion, however it is now clear that they play a major role in chronic
graft destruction (1). They are produced by T-dependent (TD) B2
B-cells with a highly diversified repertoire. This is in contrast with
preformed antibodies: anti-HLA Abs occur also following multiple
blood transfusions a condition frequently observed in patients on
the waiting list for kidney transplantation. Less often they occur
as a result of pregnancy or of previous organ transplantation,
these Abs are high affinity IgG produced by B2 B-cells. Preformed
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Antibodies also include natural Abs directed against blood group
carbohydrate determinants. These are mostly T-independent (TI)
IgM in germline configuration and are produced by a CD5neg
B1b B-cell population. Preformed Abs cause hyperacute rejection
in vascularized organs such as kidneys and heart. IgM recognize
blood groups not only on red cells but also on vascular endothe-
lium, and bind to and activate complement proteins c5–c9, thereby
forming the membrane attack complex. This complex activates
endothelial cells leading to the loss of antithrombotic molecules
and hemorrhage (2) well before cell lysis occurs. Several regula-
tory molecules such as CD55, CD46, and CD59 control unwanted
complement activation (3), however if the affinity of the Abs to the
antigen is high enough, it overcomes regulatory molecules of the
complement cascade. This is best achieved with IgG anti-HLA Abs.
At present there is no treatment of hyperacute rejection, however
prevention can be achieved by avoiding blood group disparities,
testing the recipient for anti-HLA Abs, so called “cross match” and
by plasmapheresis.
Chronic rejection
This condition generally takes 5–10 years to develop even in
patients treated with immunosuppressive drugs. Several observa-
tions have emerged from clinical practice: the process is associated
with the presence of anti-donor antibodies and is refractory to
increases in immunosuppressive therapy in contrast to acute rejec-
tion episodes. There is also a correlation between the onset of
chronic rejection and a history of acute rejection episode. Impor-
tantly, pathological manifestations include narrowing of vessels
associated with proliferation of endothelial cells and smooth
muscle cells (4). The media is progressively destroyed, cellular
proliferation halts and cells are replaced by concentric fibrosis.
In parallel there is increased expression of adhesion molecules
and of NOS, aFGF, IGF1, and endothelin. The process is TD
and involves cross priming of recipient T-cells with donor pep-
tides presented by recipient antigen presenting cells (APC) (5).
However in experimental models alloantibodies in the absence of
T-cells can induce the typical vascular changes and lesions can
develop in T-cell deficient mice. In other models graft vasculopa-
thy occurs in T-cell-deficient animal allografts but not isografts.
Yet, other models imply IFN-gamma-producing T-cells (Th1)
and IL-12-unresponsive (Th1 deficient) STAT4−/− animals show
markedly reduced severity of graft vasculopathy (6). Furthermore
the respective roles of Th1 vs. Th2 responses are far from clear
as both populations may be profibrotic and produce TGFbeta. In
addition, Th1-produced IFN-gamma has antiproliferative activity
and even propapoptotic activity on T-cells.
B-CELLS ARE PROMINENT EFFECTORS OF ALLOGRAFT REJECTION
B-cells are positive regulators of the immune response. They dif-
ferentiate in Ab-producing plasma cells. They are APC and as
such can stimulate CD4+ T-cells directly (7) although they fail
to stimulate naïve T-cells by contrast with professional (dendritic
cells) APC (8). B-cells may also stimulate T-cells by producing
cytokines, including IL-4, IL-6, and IFN-gamma. CD4+ T-cell
activation is indeed impaired in the absence of B-cells in multiple
models where B-cell development is blocked since birth (9, 10).
B-cells infiltrate chronically rejected allografts, and several groups
have reported the presence of ectopic germinal centers within
grafted tissues, so called tertiary lymphoid tissues (11–13). Thus,
a likely scenario is that B-cells present antigens to T-cells in situ
and become activated and proliferate thereby producing a variety
of antibodies including anti-self Abs (14). The role of B-cells in
chronic graft rejection is not limited to solid organs. In chronic
GVHD,B-cells from the donor contribute to the clinical manifesta-
tions of the disease and accordingly, B-cell depletion by anti-CD20
MAb/Rituximab improved steroid-resistant chronic GVHD (15).
Moreover, responses occurred before the decline in Ab titers again
suggesting a cell-mediated effect of B-cells in this process (16). B-
cell activation in this setting, is evidenced by elevated BAFF/CD257
levels in patients with active GVHD (17). Although the efficiency
of Rituximab is a proof of concept for the role of B-cells in GVHD,
the few studies conducted so far have shown limited effect in treat-
ing chronic kidney rejection furthermore Rituximab was even
deleterious as an induction therapy for acute cellular rejection
(18). This suggested that B-cells may be protective in this setting,
and strengthened the emerging concept that B-cells within the
grafted tissue can be associated with tolerance rather than rejec-
tion (19). The “tolerant” or “effector” status of graft-infiltrating
B-cells is therefore worth investigating as a prognostic factor in
organ transplantation, inasmuch as regulatory B-cells are now
much better characterized.
THE CONCEPT OF “TOLERIZING” AND REGULATORY- Breg- B-CELLS,
AGAINST AUTOIMMUNE DISEASES MAY NOW APPLY TO ALLOGENIC
TRANSPLANTATION
The observation of immunosuppressive B-cells, able to suppress
delayed type hypersensitivity (DTH) dates back to 1974 (20,
21). Since then, B-cells have been shown to inhibit inflamma-
tion and autoimmunity in various mouse models. Tolerizing
B-cells inhibited effector T-cells whether they have been polar-
ized toward effector Th1, Th17, or Th2 cells (22–24). Their effect
was often attributed to local provision of IL-10 although in
some instances TGFbeta was the prominent cytokine involved in
tolerance induction (25).
The data from this abundant literature were ultimately
translated into human studies. A CD19+CD24hiCD38hiIL-10-
producing regulatory B-cell subset similar to the murine one was
described (26). This subset is functionally impaired in human SLE
(27) and possibly in multiple sclerosis (28).
The vast majority of the data implying a protective role
for B-cells relates to autoimmune diseases however, increasing
results imply B-cells as potential inhibitors of allograft rejection.
Indeed a B-cell signature is associated with a positive outcome in
renal transplantation patients, and is characterized by increased
CD19+CD24hiCD38hiIL-10+ B-cells (29). This signature can be
useful to detect renal transplant tolerance in humans (30). Thus
in given – yet to be determined – conditions, Breg expand in
transplanted patients and are able to slow or prevent graft destruc-
tion. The other difficulty pertains to the definition of Breg-cells.
Although great strides have been made toward understanding their
phenotype, IL-10-producing (so called B10) and Breg-cells are not
synonymous although these populations clearly overlap.
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MECHANISMS OF Breg INDUCED TOLERANCE/IMMUNOSUPRESSION
The suppressive capacity of Breg on Th and inflammatory
responses has been ascribed chiefly to their secretion of IL-10.
This poses the question of how is IL-10 production optimally
triggered? In the mouse, B-cells produce high amounts of IL-10
following culture with LPS+ PMA+ Ionomycin, which mimics a
combined TLR4 and strong BCR engagement whereas LPS alone
induced IL-10 production in plasma cells but not in CD5+CD1d+
Breg-cells (31). Several other studies demonstrated that BCR-
signaling is an important component of IL-10 production. We
have observed a direct correlation between the intensity of BCR
stimulation and IL-10 secretion by a B-cell line (32). An important
outcome of BCR stimulation is a very rapid rise in intracytosolic
Ca2+ [c]. Mice with a B-cell restricted deficiency in the stro-
mal interaction molecules STIM-1 and -2 Ca2+ sensors, failed to
develop IL-10-producing Breg-cells (33). CD40 is a major effector
of Breg activation and IL-10 production, indirectly by inducing
the expression of CD5 (32) but also directly as shown by the abil-
ity of agonistic CD40 Abs to inhibit the Th1 response via IL-10
production (34). However IL-10 may be dispensable as tolerance
induction by anti-CD45RB required B-cells but was only depen-
dent on B-7, CD40, and ICAM-1 expression on B-cells but not
of IL-10 production (35). Above all, the main effect of IL-10 may
reside in the promotion of regulatory T-cells Treg (36, 37), through
induction of Foxp3 (38, 39) although IL-10 may be insufficient in
this respect and needs to be associated with cognate CD80/CD86
interactions (40).
The BCR interact with several transmembrane positive (CD19)
and negative (CD5 and CD22) regulators of signaling. Among
surface inhibitors, FcgRIIb/CD32 is of special interest as a toler-
ance inducer (41). Its inhibitory activity is chiefly based on its
immunotyrosine based inhibitory motif ITIM (42, 43). Its low
affinity ensures that it interacts with Immune complexes and not
with monomeric ligands (41) thereby explaining the efficacy of
aggregated intravenous Ig (IVIG). B-cell stimulation through the
BCR can be arrested with colligation (physiologically by immune
complexes) of FcgRIIb to the BCR. This results in phosphorylation
of ITIM on tyrosine and recruitment of the inositol phosphatase
SHIP-1 (44) and arrest of Ca2+ influx (45). Meanwhile the Src
kinase Lyn is phosphorylated which results in B-cell tolerance (46).
The advantage of CD32 is that it is the only Fc receptor present
on B-cells (47), its role in the efficacy of intravenous Ig IVIG
to treat idiopathic thrombopenic purpura ITP has been there-
fore suggested (48). Therefore, co-engagement of the BCR with
an inhibitory receptor such as CD32b, CD22 (a molecule with
an ITIM domain), or CD5 (a molecule with an atypical ITIM
domain) is worth investigating. We have indeed previously shown
that BCR cross-linked to an Fc-gammaRIIb-intracytosolic CD5
chimera, in a B-cell line downregulated BCR-mediated early sig-
naling events, notably Ca2+ influx and MAP Kinase activation
pathway (49).
PHENOTYPE OF Breg AND COMPARISONWITH OTHER
IL-10-PRODUCING B-CELLS
There is now a consensus regarding the phenotype of human
Breg [for recent reviews, see (50, 51)]. Breg-cells are CD19+IgMhi
CD24hiCD5+CD10+CD27+CD38+CD138+CD1dhi, and express
intracellular IL-10. However they cannot be sorted based on their
CD1dhi or CD24hi expression, which does not delineate discrete
B-cell subsets (unpublished results). CD10 is a marker of pro/pre
B-cells, whereas CD38+CD24hi expression marks transitional B-
cells (52). Likewise, CD5+ B-cells are very heterogeneous and in
the adult blood, they are a mixture of transitional B-cells, B1a
like B-cells, and activated/memory B2-B-cells (53). In B2-B-cells,
CD5 is optimally expressed by stimulation with a combination
of CD40-ligand and anti-IgM Abs (32) and produce IL-10. In
brief, CD5 is expressed on BCR-engaged B-cells and serves as
a negative feed-back to prevent unwanted overreactivity, in part
through the secretion of IL-10 and also by downregulating early
BCR-signaling. However CD5 expression is transient on B2 B-
cells, unless they are triggered permanently by a cognate antigen,
such as in the mice double transgenic for Hen Egg Lysozyme
HEL and anti-HEL Ig, these animals are tolerant to HEL, how-
ever tolerance is broken and autoantibodies produced when the
animals are bred into a CD5-null background (54). In contrast,
B1a cells which produce natural IgM and IL-10, express “natu-
rally” CD5, however 25% of the recently identified human B1
B-cells do not express surface CD5 (55). Thus, until recently,
there were no surface markers exclusive of Breg; the description
of T-cell Ig domain and mucin domain TIM-1 on Breg may nev-
ertheless change the picture, inasmuch as TIM-1 ligation induced
Breg to promote tolerance in mice (56). The status of the T-cell
inhibitory receptor PD-1 in Breg-cells is presently undetermined
as it is for PD-Ligands and may be of potential interest since PD-1
is also expressed on B-cells and modulate the humoral immune
response [reviewed in Ref. (57)]. Finally, it should be mentioned
that although IL-21 is the major cytokine involved in the expan-
sion of B10-cells (58), the level of IL-21R is apparently similar
in B10 and non-B10-cells, and thus is by no means a marker for
Breg-cells.
STRATEGIES TO INHIBIT B-CELL-MEDIATED REJECTION
The ultimate goal in transplantation is to achieve tolerance to
an allograft; this implies that the transplanted organ remains
functional in the absence of immunosuppressive regimen. This is
almost never achieved in humans contrary to animal models were
adoptively transferred lymphocytes can promote “infectious” tol-
erance. Current strategies (Table 1) can be summarized in two
main objectives: (1) eliminating effector B-cells or inhibiting their
differentiation in Ab-producing plasma cells, (2) expanding or
stimulating IL-10-producing B-cells/Breg.
The first task appears difficult owing to the lack of specific tar-
get. Currently as stated above, there is no indication that Rituximab
can be used to treat chronic graft rejection, however experimen-
tal data suggest that the depletion of alloreactive B-cells at the
time of the transplantation may promote tolerance by expand-
ing de novo B-cells, which become “accustomed” to the grafted
organ since the beginning of their development (59). Similarly,
a same strategy using cyclophosphamide, mycophenolate mofetil,
and mitoxantrone can be implemented in order to achieve a mixed
chimerism at the time of transplantation (60, 61). In view of the
available data, the value of a B-cell-depleting conditioning regi-
men at the onset of the transplantation, to ameliorate long term
organ acceptance should be considered as an option. In contrast
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Table 1 | Potential B-cell targets for the treatment of allograft rejection.
Target Ligand Expected mechanism
CD20 Rituximab, newly developed
mAbs
B-cell depletion
B-cell
metabolism
Cyclophosphamide,
mitoxantrone
B-cell depletion
IL-6 Neutralizing Abs Inhibition of PC/Ig
Proteasome
inhibitors
Bortezomib Inhibition PC/Ig
JAK3 Pharmacological inhibitors Inhibition of STATs/IL-6
STAT3 Inhibitors of Y705
phosphorylation
Inhibition of PC
differentiation
FcgRIIB CD32b agonists, IgG2
immune complexes
B-cell tolerance
induction
CD22 Agonistic mAbs? B-cell tolerance
induction?
CD5 CD5-BCR cross-linking Induction of B-cell
tolerance, cell cycle
arrest?
CD40±BCR CD40-ligand+anti-sIg IL-10 production
TLR9 Agonistic mAbs, CpGODN,
resiquimod, IL-10 production,
B-cell tolerance
CD25 Interleukin-2 Expansion of CD5+
B-cells, IL-10 production,
expansion of Treg cells
BAFF-receptor Soluble BAFF Production of IL-10 (B10
B-cells)
TIM-1 Agonistic mAb Stimulation of
Breg-cells
the failure of B-cell depletion strategies once chronic rejection
has started implies that redundant immune and inflammatory
mechanisms involving various immune cells operate and cannot
be halted by B-cell depletion. In this setting, expanding anti-
inflammatory/regulatory lymphocytes is currently the best thera-
peutic option.Yet a strategy to inhibit plasma-cell differentiation in
order to damp the production of anti-donor HLA Abs can be envis-
aged. The proteasome inhibitor bortezomib (62), and neutralizing
anti-IL-6 Abs are currently studied as inhibitors of plasma-cell
expansion; furthermore the anti-IL-6R MAb, Tocilizumab used
in the treatment of Rheumatoid arthritis may be effective in
transplantation (63). As STAT3 is a transcription factor needed
for plasma-cell differentiation, inhibition of STAT3 (64, 65) may
also be of interest. Drugs acting upstream STAT3, namely JAK3
inhibitors seem promising in this respect (66).
It is here worth mentioning that Abs may in some instances
be protective. The finding that catalytic antibodies able to disrupt
the amplification loop of the coagulation cascade (67) with anti-
inflammatory properties (68) may instead pave the way for the
selective use of IVIG (69) or immune complexes.
The Inhibitory B-cell signature observed in transplantations
with favorable outcome (29, 30) included FcgRIIB (70) suggesting
an in vivo stimulation of this inhibitory receptor. Another BCR-
associated ITIM bearing transmembrane receptor CD22 (71), is a
potential B-cell-specific target (72). Breg-cells can expand and be
stimulated by CD40 agonists alone or in combination with anti-Ig
(34). In addition, whereas cross-linking of CD40 by CD40-ligand
induces the maturation of B-cells, prolonged CD40 stimulation
inhibits Ig secretion and B-cell differentiation (73). Soluble BAFF
was shown to stimulate B10-cells in a mouse model (74) and may
be another attractive option. Among inducers of tolerance, the
TLR agonists were extensively studied. Agonistic stimulators of
TLR-4 or-9 were shown to suppress the course of autoimmune
diseases (75–77), which may also explain why infection with sal-
monella triggered the expansion of IL-10-producing B-cells (78).
The well established protective role of apoptotic cells (79) in induc-
ing B10-Breg-cells (80) was highlighted by the observation that
MZB and B1 B-cells recognize chromatin complexes and secrete
IL-10 through TLR9 transduction pathway (81). As CD5+ B-cells
express TLR9, secrete IL-10, and proliferate in response to IL-2
(53), expanding Breg-cells in vivo with IL-2 should be considered
as a therapeutic option inasmuch as IL-2 also expands CD25+Treg
cells (82). It is also inferred from these data that pharmacological
inhibitors of NFAT-IL-2 pathway may be detrimental in chronic
allograft rejection. The use of Rapamycin an inhibitor of TOR
and an inducer of autophagy, instead of cyclosporine and FK506,
should therefore be considered (83). Recently, the pivotal role of
IL-21 in the expansion of murine B10-cells was demonstrated
(58). Interestingly, B10-cells acquire their regulatory functions
after they have been activated by IL-21-producing CD4+T-cells
through CD40L/CD40 and CD4/MHC class-II interactions. This
may pave the way for the selection and ex vivo expansion of Breg-
cells for therapeutic purposes if it turns out that human Breg-cells
can be expanded as murine ones.
Altogether, experimental data strongly suggest that some
immunological conditions such as infections with bacterias or
helminths may surprisingly improve tolerance to allografts by
repressing harmful lymphocytes and expanding/activating protec-
tive cells among which, Breg-cells play a prominent role (Figure 1).
As transplanted organs are connected de novo to the recipient
blood stream but not lymphatics, is it likely that the toleriz-
ing signals are brought to the transplanted tissue through the
blood. Tolerant lymphocytes may also traffic, and induce toler-
ance into peripheral lymph nodes (Figure 1). A better knowledge
of the grafted tissue microenvironment and a better apprecia-
tion of the local balance between inflammatory and regulatory
cells and their temporal fate will undoubtedly lead to improve-
ments in the treatment of chronic allograft rejection. Ultimately
in situ immunomodulation may tip the balance of intra-graft B-
cells toward Breg-cells and possibly expand them locally. Alterna-
tively ex vivo expansion followed by injection of Breg-cells within
the transplanted organ can be performed. These strategies may
become therapeutic options in the future in the case of resistance
to immunosuppressive drugs.
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FIGURE 1 |The microenvironment and/or the microbiome (helminthes,
parasites, bacterias) can shift B-cells that recognize microbial antigen
in the spleen or in the transplanted organ toward regulatory B-cells
(pre B10). These cells may be generated in the spleen and colonize the
transplanted organ. In turn activated B-cells may present donor MHC
peptides to T-cells and undergo cognate T-B interactions in tertiary lymphoid
organs through CD40/CD40L, HLA-DR/TCR, and HLA-DR/CD4 interactions.
These interactions generate an amplification loop: in the presence of IL-21
secreted by T-cells, B-cells become IL-10-secreting cells, express CD5,
TIM1, and PD-1 molecules. In turn, IL-10 inhibits antigen presentation by
professional APC (Dendritic cells) and amplifies the production of Treg cells,
themselves a potent source of local IL-10. Treg cells migrate to peripheral
lymph node through the blood stream and concur to the inhibition of Th1
and Th2 polarization. In addition Treg migrate to the B-cell follicles where
they inhibit Antibody secretion and Immunoglobulin isotype switching.
POTENTIAL ADVERSE SIDE EFFECTS OF B-CELL-BASED THERAPIES:
INFECTIONS
What would be the safety of such therapies? One might
expect lesser drawbacks with B-cell-mediated therapies than with
pharmacological immunosuppressive regimens especially those
pertaining to drug toxicity. However there is no reason to believe
that infectious complications similar to those induced by immune-
suppression regimen (84) will be avoided. Indeed, activation of
Treg cells secondary to that of Breg, may reactivate latent viral
infections such as VZV, CMV, EBV, and polyoma (85). Treg cells
were also shown to inhibit HCV-specific CD8+ T-cells (86). As
mentioned above, infections and the microbiome control many
aspects of alloimmunity in transplantation (87). Interestingly,
B10 B-cells with a typical Breg phenotype were induced in an
experimental model by infecting mice with the red blood cell
parasite Babesia microti (88); this led to an enhanced suscepti-
bility to infections and associated with a rise in Treg cells, and
was not observed in B-cell-deficient mice. Altogether, it is likely
that in vivo or ex vivo amplification of Breg-cells for therapy may
lead to enhanced susceptibility to parasitic and possibly bacterial
infections.
The role of Interleukin-10 in infections is complex, it may
exacerbate T-cell dysfunctions and microbial infections. Indeed,
increased circulating IL-10 concentrations have been associated
with an adverse clinical outcome in patients with sepsis (89). In
contrast some data are consistent with a protective role for IL-
10 in kidney (90) lung (91) and heart transplant recipients (92).
IL-10 has been shown to protect from septic shock in staphylococ-
cal enterotoxin-induced shock (93). In an experimental model of
peritonitis, intravenous injection of Mesenchymal Stem Cells into
mice, albeit at a high concentration of 106cells/g body weight, pro-
tected animals by triggering IL-10 secretion by macrophages (94).
Protection depended only on IL-10 but not of cellular interactions
as MSC were trapped into the lungs and did not cross the blood
barrier. IL-10 was also shown to control the onset of irreversible
septic shock in mice (95). Altogether, strategies aimed at induc-
ing IL-10 secretion by resident intra-graft lymphocytes should be
promising and may obviate the adverse effects of systemic IL-10.
CONCLUSION
Recent progress in understanding the phenotype and functions of
tolerant B- and T-lymphocytes rendered possible their analysis in
biopsies of allograft tissues; Based on the discovery of new mole-
cular targets in lymphocytes, implementing new strategies based
on redirecting graft-infiltrating lymphocytes toward tolerance in
order to fight chronic allograft rejection is becoming foreseeable.
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